FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?
about
Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotideEfficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysisPlacebo effect in clinical trial design for irritable bowel syndromeEffect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis.Optimal management of constipation associated with irritable bowel syndromeRandomised controlled trial of mesalazine in IBS.Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome.Current Status of Celiac Disease Drug Development.The Stressometer: A Simple, Valid, and Responsive Measure of Psychological Stress in Inflammatory Bowel Disease Patients.Development and validation of a simple and multifaceted instrument, GERD-TEST, for the clinical evaluation of gastroesophageal reflux and dyspeptic symptomsAdverse events appear to unblind clinical trials in irritable bowel syndrome.Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis.Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial.The impact of psychiatric and extraintestinal comorbidity on quality of life and bowel symptom burden in functional GI disorders.Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome.Focus on the use of antidepressants to treat pediatric functional abdominal pain: current perspectives
P2860
Q26865304-1F4A376F-7C34-4948-A226-93FEABC373C6Q26991792-F9C08E3F-488B-44F7-BB8E-4024A018658CQ33586880-DE809CB9-145C-482B-8D2D-3A343456D17FQ34392861-CA10ED8F-14E0-49F5-A4F2-C22568560C7EQ35586543-110F0A44-537E-4044-8E79-E09921BC93B9Q36475502-8C9B07D3-AEE5-4FA0-83DF-52FF1C05B2E2Q37200907-6143BA19-FADB-4F2F-A5BA-E8C89029375EQ38175457-8471223A-C433-4167-BBEF-2CA41F58F375Q38503395-EF2B2A6E-EE2C-4A4E-B8F4-D8F8E2F2AB30Q38531668-A38A5312-2B0B-4798-A185-6CFDE51A8DB8Q38791641-1B759C04-B524-4BD3-A119-3E3B56E104FAQ38980010-FFCE18D8-8C22-4077-ADEB-AA398C70AB3BQ41191117-56F474E1-A20B-4970-9D2A-64813646FED3Q43439726-4B0FB7E0-5336-4449-82AF-F0A723A5E7EDQ46058450-A54C7B20-EB9B-4814-9B26-8E9981E2C2EFQ47811253-C08D1D94-FD1A-408A-A7B3-8F62F3535303Q47839717-D244A618-44C9-4EC7-A999-123A53C611DCQ48274669-EE895E25-B0BD-45AE-9B8F-017FE20B44D9Q57489996-C26D68D2-2132-46C7-B4C8-7C90CC59F3AB
P2860
FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
FDA and EMA end points: which ...... with irritable bowel syndrome?
@en
FDA and EMA end points: which ...... with irritable bowel syndrome?
@nl
type
label
FDA and EMA end points: which ...... with irritable bowel syndrome?
@en
FDA and EMA end points: which ...... with irritable bowel syndrome?
@nl
prefLabel
FDA and EMA end points: which ...... with irritable bowel syndrome?
@en
FDA and EMA end points: which ...... with irritable bowel syndrome?
@nl
P2860
P356
P1476
FDA and EMA end points: which ...... with irritable bowel syndrome?
@en
P2093
P2860
P304
P356
10.1111/NMO.12151
P577
2013-06-01T00:00:00Z